Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community

Clinical Genitourinary Cancer
Guru SonpavdeNicholas J Vogelzang

Abstract

Renal dysfunction, poor performance status, and comorbidities may preclude frontline cisplatin-based chemotherapy in patients with advanced urothelial carcinoma (UC). The frequency of cisplatin-based chemotherapy administration in patients with advanced UC in community-based cancer centers is unknown. A retrospective study was conducted to evaluate chemotherapy regimens administered to patients with the AJCC (American Joint Committee on Cancer) stage-4 UC who, from 2001 to 2010, presented to Texas Oncology Cancer Centers. Frontline chemotherapy was classified as cisplatin based, carboplatin based, nonplatinum based, and as no chemotherapy administered. A total of 298 patients were eligible for analysis, of whom 197 (66.1%) were men. The median age was 70 years (range, 28-97 years), and the primary sites of disease were bladder (243 [81.5%]), renal pelvis (41 [13.8%]), and ureter (14 [4.7%]). Overall, the regimens administered were cisplatin based in 107 patients (35.9%), carboplatin based in 81 (27.2%), and nonplatinum based in 25 (8.4%); no chemotherapy was administered in 71 (23.8%), and data were not available in 14 patients (4.7%). Cisplatin administration was more common in patients aged ≤70 years (62/150 [41.3%]) as oppos...Continue Reading

References

Jul 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans von der MaaseMichael Arning
Jul 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guru SonpavdeNicholas J Vogelzang
May 11, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew D GalskyJoaquim Bellmunt

❮ Previous
Next ❯

Citations

Nov 5, 2015·Expert Opinion on Investigational Drugs·Costantine Albany, Guru Sonpavde
May 16, 2013·Clinical Genitourinary Cancer·Lindsay HainesMatthew D Galsky
Apr 16, 2015·Cancer·Matthew D GalskyUNKNOWN Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators
Feb 23, 2013·Urologic Oncology·Matthew D GalskyAristotle Bamias
Apr 4, 2015·Hematology/oncology Clinics of North America·Guru SonpavdeCora N Sternberg
Mar 10, 2018·Current Treatment Options in Oncology·Ariel E Marciscano, Ravi A Madan
Jun 28, 2019·Nature Communications·Maria StrackBin Xu
Dec 24, 2018·Therapeutic Advances in Urology·Alfonso Gómez De Liaño, Ignacio Duran
Jul 9, 2017·Annals of Surgical Oncology·Tohru NakagawaYukio Homma
Aug 14, 2020·International Journal of Molecular Sciences·Martina MinoliRoland Seiler
Jun 20, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jacqueline VukyElizabeth R Plimack
Nov 20, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Judit BörcsökZoltan Szallasi
May 6, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Judit BörcsökZoltan Szallasi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Auditory Perception

Auditory perception is the ability to receive and interpret information attained by the ears. Here is the latest research on factors and underlying mechanisms that influence auditory perception.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Matthew D GalskyGuru Sonpavde
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Rafael Morales-BarreraJ Carles
© 2022 Meta ULC. All rights reserved